Inhaltsbereich
| 50 Einträge | 1, 2, 3 › » |
Seite 1 / 3
 Druckansicht
|
| The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. |
| Schwameis R, Grimm C, Petru E, Natter C, Staudigl C, Lamm W, Koelbl H, Krainer M, Brodowicz T, Reinthaller A, Polterauer S |
| PloS one. 2015 Aug 6. doi: 10.1371/journal.pone.0133838. pii: PONE-D-15-00258. pmc: PMC4527693 |
| PMID: 26248232 |
| Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. |
| Kratochvílová K, Horak P, Ešner M, Souček K, Pils D, Anees M, Tomasich E, Dráfi F, Jurtíková V, Hampl A, Krainer M, Vaňhara P |
| International journal of cancer. Journal international du cancer. 2015 Mar 21. doi: 10.1002/ijc.29502 |
| PMID: 25735931 |
| Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma. |
| Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S |
| BMC cancer. 2014 Dec 18. pii: 1471-2407-14-981. doi: 10.1186/1471-2407-14-981. pmc: PMC4320583 |
| PMID: 25523155 |
| HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. |
| Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, Krainer M, Horak P |
| Molecular cancer research : MCR. 2014 Oct 27. pii: 1541-7786.MCR-14-0153-T. doi: 10.1158/1541-7786.MCR-14-0153-T |
| PMID: 25349289 |
| The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB. |
| Anees M, Horak P, Schiefer AI, Vaňhara P, El-Gazzar A, Perco P, Kiesewetter B, Müllauer L, Streubel B, Raderer M, Krainer M |
| Leukemia & lymphoma. 2014 Nov 5. doi: 10.3109/10428194.2014.953149 |
| PMID: 25248880 |
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. |
| Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR |
| The Lancet. Oncology. 2014 May 13. pii: S1470-2045(14)70189-5. doi: 10.1016/S1470-2045(14)70189-5. pmc: PMC4418935. mid: NIHMS677780 |
| PMID: 24831977 |
| TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. |
| Horak P, Tomasich E, Vaňhara P, Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M, Horvat R, Sibilia M, Pils D, Krainer M |
| Scientific reports. 2014 Jan 17. pii: srep03739. doi: 10.1038/srep03739. pmc: PMC3894551 |
| PMID: 24435307 |
| IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. |
| Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M |
| Cell death and differentiation. 2013 Mar 1. pii: cdd201315. doi: 10.1038/cdd.2013.15. pmc: PMC3647237 |
| PMID: 23449395 |
| Methylation status of TUSC3 is a prognostic factor in ovarian cancer. |
| Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M |
| Cancer. 2012 Oct 23. doi: 10.1002/cncr.27850 |
| PMID: 23096450 |
| HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. |
| Perisanidis C, Savarese-Brenner B, Würger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M |
| Oral diseases. 2012 Aug 14. doi: 10.1111/j.1601-0825.2012.01972.x |
| PMID: 22891969 |
| hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. |
| Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Oct 20. pii: 1078-0432.CCR-11-0408. doi: 10.1158/1078-0432.CCR-11-0408 |
| PMID: 22016507 |
| Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. |
| Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK |
| Cancer. 2010 Nov 8. doi: 10.1002/cncr.25504 |
| PMID: 21381010 |
| Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. |
| Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R |
| BMC cancer. 2010 Dec 3. pii: 1471-2407-10-666. doi: 10.1186/1471-2407-10-666. pmc: PMC3013085 |
| PMID: 21129172 |
| Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. |
| El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T, Zheng D, Krainer M |
| Molecular cancer therapeutics. 2010 Apr 6. pii: 1535-7163.MCT-09-0933. doi: 10.1158/1535-7163.MCT-09-0933 |
| PMID: 20371719 |
| The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. |
| El-Gazzar A, Wittinger M, Perco P, Anees M, Horvat R, Mikulits W, Grunt TW, Mayer B, Krainer M |
| Gynecologic oncology. 2010 Mar 15. pii: S0090-8258(10)00180-0. doi: 10.1016/j.ygyno.2010.02.024 |
| PMID: 20227749 |
| BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment. |
| Pils D, Wittinger M, Petz M, Gugerell A, Gregor W, Alfanz A, Horvat R, Braicu EI, Sehouli J, Zeillinger R, Mikulits W, Krainer M |
| Gynecologic oncology. 2010 Feb 26. pii: S0090-8258(10)00119-8. doi: 10.1016/j.ygyno.2009.12.034 |
| PMID: 20189233 |
| Targeting signaling pathways in ovarian cancer. |
| Reibenwein J, Krainer M |
| Expert opinion on therapeutic targets. 2008 Feb 13. doi: 10.1517/14728222.12.3.353 |
| PMID: 18269344 |
| Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. |
| Kirisits A, Pils D, Krainer M |
| The international journal of biochemistry & cell biology. 2007 Aug 1. pii: S1357-2725(07)00250-6. doi: 10.1016/j.biocel.2007.07.012 |
| PMID: 17855153 |
| A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. |
| Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M, Höltl W, Schramek P, Stackl W, Zielinski C, Reibenwein J |
| The Journal of urology. 2007 May 18. pii: S0022-5347(07)00286-8. doi: 10.1016/j.juro.2007.01.148 |
| PMID: 17509302 |
| In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. |
| Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L, Horvat R, Reinthaller A, Zeillinger R, Krainer M |
| British journal of cancer. 2007 Jan 23. pii: 6603581. doi: 10.1038/sj.bjc.6603581. pmc: PMC2360022 |
| PMID: 17245339 |
| 50 Einträge | 1, 2, 3 › » |
Seite 1 / 3
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
